🇺🇸 FDA
Patent

US 8252550

Targeting poly-γ-glutamic acid to treat Staphylococcus epidermidis and related infections

granted A61KA61K2039/6037A61K2039/6056

Quick answer

US patent 8252550 (Targeting poly-γ-glutamic acid to treat Staphylococcus epidermidis and related infections) held by The United States of America as Represented by the Secretary of the Department of Health and Human Services expires Mon Aug 23 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America as Represented by the Secretary of the Department of Health and Human Services
Grant date
Tue Aug 28 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 23 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
4
CPC classes
A61K, A61K2039/6037, A61K2039/6056, A61K2039/6081, A61K39/085